Do copper peptides actually work according to clinical and preclinical studies?

Copper tripeptide demonstrates repeatable biological activity in both preclinical studies and a limited number of human trials, particularly in areas such as skin regeneration, wound healing, and tissue remodeling. However, the strength of the evidence depends on the specific application and remains limited for systemic effects. *In vitro* and animal studies indicate that copper peptide enhances collagen production, supports angiogenesis, regulates repair-related genes, and accelerates wound closure. These findings support its influence on regenerative processes and tissue rebuilding [1,2]. Improved extracellular matrix formation and reduced tissue damage under stress conditions have also been observed in many experimental models.

Human study data are available, but they mainly concern topical applications. Clinical studies using copper peptide-containing preparations show improvements in skin quality, including increased thickness, better elasticity, and reduced wrinkle visibility over 8–12 weeks [3,4]. In wound treatment, including diabetic ulcers, controlled studies have demonstrated faster healing compared to standard methods, indicating its effect on local tissue regeneration [5]. However, it should be emphasized that most studies involve small groups and focus on skin or surface tissues, rather than systemic effects.

From a mechanistic viewpoint, copper peptide acts as a signaling molecule. This means it regulates biological processes, such as gene expression, growth factor production, and antioxidant mechanisms, rather than acting like a classic drug requiring high doses. This explains why effects are observed at relatively low concentrations under controlled conditions. Copper peptide used in research is available through suppliers like SemaxPolska. While current data support its biological activity, they do not provide evidence of broad clinical efficacy in all applications, especially in the context of systemic action.

What clinical trials in humans are there concerning copper peptide and what are their results?

Clinical trials involving humans on copper peptide primarily focus on skin and wound healing, with results indicating measurable improvement in tissue regeneration and skin condition. One of the most well-known controlled studies involved patients with diabetic foot ulcers and showed significantly faster healing compared to standard treatment, confirming its role in the regeneration of damaged skin [5].

In cosmetic dermatology, both placebo-controlled and open-label studies have been conducted using copper peptide-containing creams for several weeks. These studies have shown an increase in skin thickness, improved elasticity, reduced fine wrinkles, and an overall improvement in skin appearance [3,4]. Some studies involving dozens of participants observed changes in skin structure, indicating an effect on dermal remodeling. Additional studies on UV-damaged skin and regeneration after dermatological procedures have also shown improved healing and reduced visible damage after topical application [6].

Despite these results, there are significant limitations. The number of large, well-designed, multicenter clinical trials remains small. Most studies focus on topical application, and high-quality data regarding other administration routes, such as oral, injectable, or intranasal in humans, are limited. Current clinical data support its efficacy within the skin but do not confirm broad medical applications across various conditions.

Areas of research into copper tripeptide have the strongest evidence in:

The strongest evidence concerns the action of copper tripeptide in skin regeneration, wound healing, and regulation of cellular repair processes. Wound healing is one of the best-documented areas. Studies show faster tissue regeneration, increased collagen deposition, improved blood vessel formation, and more effective wound closure in various experimental models [2, 7]. Clinical trial results for diabetic ulcers further confirm these observations [5].

Another well-documented area is skin aging and cosmetic dermatology. Numerous studies show that copper peptide improves skin texture, increases collagen and elastin production, and reduces visible signs of aging. These effects have been confirmed in controlled clinical trials, which noted improvements in skin thickness, elasticity, and appearance [3]. Gene expression studies also indicate that copper peptide affects many genes related to repair, inflammation control, and antioxidant protection, highlighting its role as a regulator of biological processes [8].

Other areas, such as neuroprotection, anti-inflammatory action, or general tissue regeneration, are still under development. Although preclinical studies show promising results, confirmation in clinical trials with humans is limited. The copper peptide used in the studies is available through suppliers such as SemaxPolska. Currently, the strongest evidence relates to topical applications and local tissue regeneration, and laboratory and animal study results should not be directly extrapolated to broad clinical applications without further research.

References

1. Pickart, L. (2008). The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 19(8), 969–988.
2. Siméon, A., Monier, F., Emonard, H., Gillery, P., & Maquart, F. X. (1999). Expression and activation of matrix metalloproteinases in wounds: Modulation by the tripeptide–copper complex glycyl-L-histidyl-L-lysine-Cu2+. Journal of Investigative Dermatology, 112(6), 957–964.
3. Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of new gene data. International Journal of Molecular Sciences, 19(7), 1987.
4. Badenhorst, T., Svirskis, D., Merrilees, M., & Bolke, L. (2016). Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science, 4(2), 1–8.
5. Mulder, G. D., Patt, L. M., Sanders, L., Rosenstock, J., Altman, M. I., Hanley, M. E., & Duncan, G. W. (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration, 2(4), 259–269.
6. Miller, T. R., Wagner, J. D., Baack, B. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser–resurfaced skin. Archives of Facial Plastic Surgery, 8(4), 239–243.
7. Wang, X., Liu, B., Xu, Q., Sun, H., Shi, M., & Zhang, L. (2017). GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair and Regeneration, 25(2), 280–287.
8. Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics, 2(3), 236–247.